Trial reportESC heart failure2020
Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.
Trial report in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.Cardiovascular drugs and therapy · 2021Pooled it
- A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia.Clinical and experimental nephrology · 2021Trial
- Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.ESC heart failure · 2020Trial
- The Endoscopic Removal of a Gastric Bezoar Made of Sodium Zirconium Cyclosilicate Hydrate.Internal medicine (Tokyo, Japan) · 2026Article
- Management of hyperkalaemia in the Italian clinical practice: impact of diverse potassium binders on outcomes and costs in patients with chronic kidney disease and heart failure.International urology and nephrology · 2026Article
- Sodium zirconium cyclosilicate post hospital discharge to prevent hyperkalaemia: phase 4, randomized CONTINUITY trial.Clinical kidney journal · 2026Article
- Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate.Electrolyte & blood pressure : E & BP · 2026Review
- [Consensus recommendations on the diagnosis and treatment of hyperkalemia of the Austrian Society of Nephrology 2026].Wiener klinische Wochenschrift · 2026Review
- Effect of Sodium Zirconium Cyclosilicate Approval on the Management of Acute Hyperkalemia in Japan: Interrupted Time Series Analysis.American journal of nephrology · 2026Article
- Overcoming Hyperkalaemia to Optimise Heart Failure Therapy: The Emerging Role of Novel Potassium Binders.Cardiac failure review · 2026Review
- Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review.Advances in therapy · 2025Review
- Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.BMC nephrology · 2025Article
- Prognostic Impact of Long-Term Sodium Zirconium Cyclosilicate-Integrated Medical Therapy in Patients with Systolic Heart Failure.Journal of clinical medicine · 2025Article
- Article
- A Case of Sigmoid Colon Perforation Associated with Sodium Zirconium Cyclosilicate in a Patient with Advanced Rectal Cancer.Surgical case reports · 2025Article
- EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and Heart Failure.Cardiorenal medicine · 2025Review
- Article
- Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.Journal of nephrology · 2024Observational
- Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis.Pediatric nephrology (Berlin, Germany) · 2024Article
- Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities.Internal and emergency medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 9 countries.
Funding
Abstract
aimsSodium zirconium cyclosilicate (SZC, formerly ZS-9) is a selective K METHODS AND
resultsThis phase 3, randomized, double-blind, placebo-controlled study recruited outpatients with serum K
conclusionsNormokalaemia achieved during the CP was maintained over 28 days with SZC treatment among outpatients with hyperkalaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.